- Home
- CKPT vs SENS Comparison
CKPT vs SENS Comparison
Compare CKPT & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- SENS
- Stock Information
- Founded
- CKPT 2014
- SENS 1996
- Country
- CKPT United States
- SENS United States
- Employees
- CKPT N/A
- SENS N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- SENS Industrial Machinery/Components
- Sector
- CKPT Health Care
- SENS Industrials
- Exchange
- CKPT Nasdaq
- SENS Nasdaq
- Market Cap
- CKPT 335.9M
- SENS 392.5M
- IPO Year
- CKPT 2017
- SENS N/A
- Fundamental
- Price
- CKPT $4.17
- SENS $0.63
- Analyst Decision
- CKPT Buy
- SENS Strong Buy
- Analyst Count
- CKPT 3
- SENS 2
- Target Price
- CKPT $4.33
- SENS $2.00
- AVG Volume (30 Days)
- CKPT 1.0M
- SENS 3.1M
- Earning Date
- CKPT 05-16-2025
- SENS 05-08-2025
- Dividend Yield
- CKPT N/A
- SENS N/A
- EPS Growth
- CKPT N/A
- SENS N/A
- EPS
- CKPT N/A
- SENS N/A
- Revenue
- CKPT $41,000.00
- SENS $23,682,000.00
- Revenue This Year
- CKPT $102,182.93
- SENS $60.14
- Revenue Next Year
- CKPT $351.71
- SENS $36.55
- P/E Ratio
- CKPT N/A
- SENS N/A
- Revenue Growth
- CKPT N/A
- SENS 1.64
- 52 Week Low
- CKPT $1.47
- SENS $0.25
- 52 Week High
- CKPT $4.50
- SENS $1.40
- Technical
- Relative Strength Index (RSI)
- CKPT 71.99
- SENS 43.79
- Support Level
- CKPT $4.02
- SENS $0.65
- Resistance Level
- CKPT $4.17
- SENS $0.75
- Average True Range (ATR)
- CKPT 0.03
- SENS 0.05
- MACD
- CKPT -0.01
- SENS -0.00
- Stochastic Oscillator
- CKPT 93.33
- SENS 4.91
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.